Skip to main content
. 2020 Dec 28;15(12):e0244502. doi: 10.1371/journal.pone.0244502

Fig 4. Flow chart illustrating the potential utility of our scoring system in the management of patients with EGFR-mutated lung adenocarcinoma treated with TKI.

Fig 4

EGFR: Epidermal growth factor receptor, TKI: Tyrosine kinase inhibitor, PFS: Progression-free survival, OS: Overall survival, HR: Hazard ratio.